Tango Therapeutics, Inc. (TNGX) – What Are Investment Firms Saying About This Stock?

Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) have earned an average recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and thirteen have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $45.54.

Several brokerages have issued reports on TNGX. Guggenheim lifted their price objective on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. William Blair started coverage on Tango Therapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Zacks Research cut Tango Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 27th. Mizuho raised their target price on Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th.

Tango Therapeutics Trading Up 6.9%

NASDAQ:TNGX opened at $24.30 on Wednesday. Tango Therapeutics has a 1 year low of $7.49 and a 1 year high of $34.39. The firm has a 50 day moving average of $23.35 and a 200-day moving average of $22.59. The stock has a market capitalization of $4.10 billion, a P/E ratio of -17.74 and a beta of 1.26.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). As a group, analysts forecast that Tango Therapeutics will post -1.41 EPS for the current fiscal year.

Trending Headlines about Tango Therapeutics

Here are the key news stories impacting Tango Therapeutics this week:

• Positive Sentiment: A Phase 1/2 combination study of vopimetostat and daraxonrasib in second- and third-line pancreatic cancer reported an 82% objective response rate and 88% nine-month progression-free survival, with the regimen generally well tolerated. Tango expects to start a registrational Phase 3 trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. The company also reported $977.5 million in cash as of September 30. Tango Therapeutics Q3 2026 results and business highlights
• Positive Sentiment: JPMorgan raised its price target to $47 from $46 and maintained an Overweight rating, signaling continued optimism about TNGX’s prospects. JPMorgan analyst recommendations
• Neutral Sentiment: A report listed short interest at zero shares and a zero days-to-cover ratio. This unusually low reported figure offers little clear indication of investor positioning.
• Negative Sentiment: Tango reported a third-quarter loss of $0.39 per share, missing the analyst consensus estimate of a $0.35 loss by $0.04. Tango Therapeutics quarterly earnings press release
• Negative Sentiment: Wedbush cut its target to $40 from $45, while retaining an Outperform rating; HC Wainwright lowered its target to $67 from $68 but kept a Buy rating. The reductions temper the bullish analyst outlook, although both targets remain above the stock’s cited $24.30 price. Wedbush analyst recommendations HC Wainwright analyst recommendations

Insider Activity

In other Tango Therapeutics news, insider Jessica Newcomb sold 8,200 shares of the stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the sale, the insider owned 59,121 shares of the company’s stock, valued at $1,431,910.62. This represents a 12.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $24.47, for a total transaction of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 47,231 shares of company stock worth $1,129,029. 6.50% of the stock is owned by corporate insiders.

Institutional Trading of Tango Therapeutics

Several hedge funds have recently modified their holdings of TNGX. BlackRock Inc. acquired a new stake in shares of Tango Therapeutics in the second quarter valued at approximately $388,826,000. TRV GP IV LLC bought a new position in Tango Therapeutics in the 2nd quarter worth approximately $120,181,383,000. Jupiter Topco LLC bought a new position in Tango Therapeutics in the 2nd quarter worth approximately $157,989,000. Seven Fleet Capital Management LP lifted its holdings in Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock worth $95,661,000 after buying an additional 2,425,484 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in Tango Therapeutics during the 2nd quarter worth $62,849,000. 78.99% of the stock is owned by institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.